Research Applications
Rapid-onset antidepressant research. TREK-1 channel pharmacology. Non-monoaminergic depression treatment. Treatment-resistant depression.
Mechanism of Action
Spadin selectively blocks TREK-1 potassium channels, increasing neuronal excitability in hippocampus and cortex. TREK-1 blockade enhances serotonergic neurotransmission, increases BDNF expression and hippocampal neurogenesis, and activates CREB signaling — effects similar to chronic SSRI treatment but occurring within days.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All ProtocolsResearch Studies
Spadin: A Novel Antidepressant Targeting TREK-1
Mazella J, Petrault O, Lucas G, et al.






